CBiPES
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H19N3O2S |
| Molar mass | 377.46 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
CBiPES is a drug used in scientific research that acts as a selective positive allosteric modulator for the metabotropic glutamate receptor group II subtype mGluR2. It has potentially antipsychotic effects in animal models, and is used for researching the role of mGluR2 receptors in schizophrenia and related disorders.[1][2][3]
References
[edit]- ^ Johnson MP, Barda D, Britton TC, Emkey R, Hornback WJ, Jagdmann GE, et al. (April 2005). "Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)". Psychopharmacology. 179 (1): 271–83. doi:10.1007/s00213-004-2099-9. PMID 15717213. S2CID 2699540.
- ^ Fell MJ, Katner JS, Johnson BG, Khilevich A, Schkeryantz JM, Perry KW, Svensson KA (March 2010). "Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge". Neuropharmacology. 58 (3): 632–9. doi:10.1016/j.neuropharm.2009.11.014. PMID 19951716. S2CID 7262560.
- ^ Sanger H, Hanna L, Colvin EM, Grubisha O, Ursu D, Heinz BA, et al. (March 2013). "Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR". Neuropharmacology. 66: 264–73. doi:10.1016/j.neuropharm.2012.05.023. PMID 22659090. S2CID 42448364.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |